论文信息 - A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. - 字舞流文

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

R. Salazar | R. Riechelmann | E. Van Cutsem | N. Fazio | C. Lombard-Bohas | P. Ruszniewski | M. Pavel | J. Valle | I. Borbath | M. Voi | J. Capdevila | M. Kulke | W. D. de Herder | J. C. Brase | J. Yao | E. Degtyarev | L. Bubuteishvili-Pacaud | D. Smith